Keith D Taylor sold $689k of EQIX
Chief Financial Officer at EQUINIX INC. 822 shares at an average of $838.48, traded Mar 13, 2025, filed Mar 14, 2025.
Score components
- +22RoleCFO
- +21Trade size$689k at market
- 0Share of holdings soldSold 3.3% of holdings
- +15Cluster8 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -7.3%, 3m +7.1%, 6m -4.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001127602-25-009491, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 12, 2025 | MOption exercise Common Stock10b5-1 | +822 | $0.00 | $0 | 25,224 | Mar 14, 2025 |
| Mar 13, 2025 | SOpen-market sale Common Stock10b5-1 | -123 | $830.77 | $102k | 25,101 | Mar 14, 2025 |
| Mar 13, 2025 | SOpen-market sale Common Stock10b5-1 | -164 | $832.23 | $136k | 24,937 | Mar 14, 2025 |
| Mar 13, 2025 | SOpen-market sale Common Stock10b5-1 | -2 | $832.87 | $1,666 | 24,935 | Mar 14, 2025 |
| Mar 13, 2025 | SOpen-market sale Common Stock10b5-1 | -82 | $834.36 | $68k | 24,853 | Mar 14, 2025 |
| Mar 13, 2025 | SOpen-market sale Common Stock10b5-1 | -82 | $835.62 | $69k | 24,771 | Mar 14, 2025 |
| Mar 13, 2025 | SOpen-market sale Common Stock10b5-1 | -41 | $838.59 | $34k | 24,730 | Mar 14, 2025 |
| Mar 13, 2025 | SOpen-market sale Common Stock10b5-1 | -41 | $843.87 | $35k | 24,689 | Mar 14, 2025 |
| Mar 13, 2025 | SOpen-market sale Common Stock10b5-1 | -82 | $845.38 | $69k | 24,607 | Mar 14, 2025 |
| Mar 13, 2025 | SOpen-market sale Common Stock10b5-1 | -82 | $846.43 | $69k | 24,525 | Mar 14, 2025 |
| Mar 13, 2025 | SOpen-market sale Common Stock10b5-1 | -82 | $847.17 | $69k | 24,443 | Mar 14, 2025 |
| Mar 13, 2025 | SOpen-market sale Common Stock10b5-1 | -41 | $848.21 | $35k | 24,402 | Mar 14, 2025 |
| Mar 12, 2025 | AGrant or award Restricted Stock Unitderivative10b5-1 | +822 | $0.00 | $0 | 822 | Mar 14, 2025 |
| Mar 12, 2025 | MOption exercise Restricted Stock Unitderivative10b5-1 | -822 | $0.00 | $0 | 0 | Mar 14, 2025 |
Related signals
Other insiders at EQUINIX INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 34Weak | EQIXsell EQUINIX INC | Michael Shane Paladin Chief Customer & Rev Officer | $318k 307 shares | -11% | |
| 0Weak | EQUINIX INC | Michael Shane Paladin Chief Customer & Rev Officer | $206k 203 shares | -7% | |
| 21Weak | EQUINIX INC | Kurt Pletcher Chief Legal Officer | $145k 135 shares | -3% | |
| 14Weak | EQUINIX INC | Christopher B Paisley director | $138k 125 shares | -1% | |
| 45Moderate | EQIXsell EQUINIX INC | Christopher B Paisley director | $4.1M 4,000 shares | -22% | |
| 45Moderate | EQUINIX INC | Brandi Galvin Morandi Chief People Officer | $4.0M 3,726 shares | -38% | |
| 6Weak | EQUINIX INC | Raouf Abdel EVP, Global Operations | $168k 158 shares | -3% | |
| 35Weak | EQUINIX INC | Adaire Fox-Martin CEO and President | $3.1M 2,935 shares | -12% | |
| 6Weak | EQUINIX INC | Jonathan Lin Chief Business Officer | $159k 150 shares | -1% | |
| 4Weak | EQUINIX INC | Kurt Pletcher Chief Legal Officer | $84k 79 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.